SGLT inhibitors in management of diabetes

Abd A. Tahrani, Anthony H. Barnett, Clifford J. Bailey

Research output: Contribution to journalArticle

Abstract

The two main sodium-glucose cotransporters (SGLTs), SGLT1 and SGLT2, provide new therapeutic targets to reduce hyperglycaemia in patients with diabetes. SGLT1 enables the small intestine to absorb glucose and contributes to the reabsorption of glucose filtered by the kidney. SGLT2 is responsible for reabsorption of most of the glucose filtered by the kidney. Inhibitors with varying specificities for these transporters (eg, dapagliflozin, canagliflozin, and empagliflozin) can slow the rate of intestinal glucose absorption and increase the renal elimination of glucose into the urine. Results of randomised clinical trials have shown the blood glucose-lowering efficacy of SGLT inhibitors in type 2 diabetes when administered as monotherapy or in addition to other glucose-lowering therapies including insulin. Increased renal glucose elimination also assists weight loss and could help to reduce blood pressure. Effective SGLT2 inhibition needs adequate glomerular filtration and might increase risk of urinary tract and genital infection, and excessive inhibition of SGLT1 can cause gastro-intestinal symptoms. However, the insulin-independent mechanism of action of SGLT inhibitors seems to offer durable glucose-lowering efficacy with low risk of clinically significant hypoglycaemia at any stage in the natural history of type 2 diabetes. SGLT inhibition might also be considered in conjunction with insulin therapy in type 1 diabetes.
Original languageEnglish
Pages (from-to)140-151
Number of pages12
JournalThe Lancet Diabetes and Endocrinology
Volume1
Issue number2
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Sodium-Glucose Transport Proteins
Glucose
Insulin
Type 2 Diabetes Mellitus
Kidney
Intestinal Absorption
Type 1 Diabetes Mellitus
Hypoglycemia
Urinary Tract Infections
Hyperglycemia
Small Intestine
Blood Glucose
Weight Loss
Therapeutics
Randomized Controlled Trials
Urine
Blood Pressure

Cite this

Tahrani, Abd A. ; Barnett, Anthony H. ; Bailey, Clifford J. / SGLT inhibitors in management of diabetes. In: The Lancet Diabetes and Endocrinology. 2013 ; Vol. 1, No. 2. pp. 140-151.
@article{4f50d0f46cac4307aebb36e5b2846d96,
title = "SGLT inhibitors in management of diabetes",
abstract = "The two main sodium-glucose cotransporters (SGLTs), SGLT1 and SGLT2, provide new therapeutic targets to reduce hyperglycaemia in patients with diabetes. SGLT1 enables the small intestine to absorb glucose and contributes to the reabsorption of glucose filtered by the kidney. SGLT2 is responsible for reabsorption of most of the glucose filtered by the kidney. Inhibitors with varying specificities for these transporters (eg, dapagliflozin, canagliflozin, and empagliflozin) can slow the rate of intestinal glucose absorption and increase the renal elimination of glucose into the urine. Results of randomised clinical trials have shown the blood glucose-lowering efficacy of SGLT inhibitors in type 2 diabetes when administered as monotherapy or in addition to other glucose-lowering therapies including insulin. Increased renal glucose elimination also assists weight loss and could help to reduce blood pressure. Effective SGLT2 inhibition needs adequate glomerular filtration and might increase risk of urinary tract and genital infection, and excessive inhibition of SGLT1 can cause gastro-intestinal symptoms. However, the insulin-independent mechanism of action of SGLT inhibitors seems to offer durable glucose-lowering efficacy with low risk of clinically significant hypoglycaemia at any stage in the natural history of type 2 diabetes. SGLT inhibition might also be considered in conjunction with insulin therapy in type 1 diabetes.",
author = "Tahrani, {Abd A.} and Barnett, {Anthony H.} and Bailey, {Clifford J.}",
year = "2013",
month = "10",
doi = "10.1016/S2213-8587(13)70050-0",
language = "English",
volume = "1",
pages = "140--151",
journal = "The Lancet Diabetes and Endocrinology",
issn = "2213-8587",
publisher = "Elsevier",
number = "2",

}

SGLT inhibitors in management of diabetes. / Tahrani, Abd A.; Barnett, Anthony H.; Bailey, Clifford J.

In: The Lancet Diabetes and Endocrinology, Vol. 1, No. 2, 10.2013, p. 140-151.

Research output: Contribution to journalArticle

TY - JOUR

T1 - SGLT inhibitors in management of diabetes

AU - Tahrani, Abd A.

AU - Barnett, Anthony H.

AU - Bailey, Clifford J.

PY - 2013/10

Y1 - 2013/10

N2 - The two main sodium-glucose cotransporters (SGLTs), SGLT1 and SGLT2, provide new therapeutic targets to reduce hyperglycaemia in patients with diabetes. SGLT1 enables the small intestine to absorb glucose and contributes to the reabsorption of glucose filtered by the kidney. SGLT2 is responsible for reabsorption of most of the glucose filtered by the kidney. Inhibitors with varying specificities for these transporters (eg, dapagliflozin, canagliflozin, and empagliflozin) can slow the rate of intestinal glucose absorption and increase the renal elimination of glucose into the urine. Results of randomised clinical trials have shown the blood glucose-lowering efficacy of SGLT inhibitors in type 2 diabetes when administered as monotherapy or in addition to other glucose-lowering therapies including insulin. Increased renal glucose elimination also assists weight loss and could help to reduce blood pressure. Effective SGLT2 inhibition needs adequate glomerular filtration and might increase risk of urinary tract and genital infection, and excessive inhibition of SGLT1 can cause gastro-intestinal symptoms. However, the insulin-independent mechanism of action of SGLT inhibitors seems to offer durable glucose-lowering efficacy with low risk of clinically significant hypoglycaemia at any stage in the natural history of type 2 diabetes. SGLT inhibition might also be considered in conjunction with insulin therapy in type 1 diabetes.

AB - The two main sodium-glucose cotransporters (SGLTs), SGLT1 and SGLT2, provide new therapeutic targets to reduce hyperglycaemia in patients with diabetes. SGLT1 enables the small intestine to absorb glucose and contributes to the reabsorption of glucose filtered by the kidney. SGLT2 is responsible for reabsorption of most of the glucose filtered by the kidney. Inhibitors with varying specificities for these transporters (eg, dapagliflozin, canagliflozin, and empagliflozin) can slow the rate of intestinal glucose absorption and increase the renal elimination of glucose into the urine. Results of randomised clinical trials have shown the blood glucose-lowering efficacy of SGLT inhibitors in type 2 diabetes when administered as monotherapy or in addition to other glucose-lowering therapies including insulin. Increased renal glucose elimination also assists weight loss and could help to reduce blood pressure. Effective SGLT2 inhibition needs adequate glomerular filtration and might increase risk of urinary tract and genital infection, and excessive inhibition of SGLT1 can cause gastro-intestinal symptoms. However, the insulin-independent mechanism of action of SGLT inhibitors seems to offer durable glucose-lowering efficacy with low risk of clinically significant hypoglycaemia at any stage in the natural history of type 2 diabetes. SGLT inhibition might also be considered in conjunction with insulin therapy in type 1 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84884502673&partnerID=8YFLogxK

U2 - 10.1016/S2213-8587(13)70050-0

DO - 10.1016/S2213-8587(13)70050-0

M3 - Article

AN - SCOPUS:84884502673

VL - 1

SP - 140

EP - 151

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

SN - 2213-8587

IS - 2

ER -